Our Pricing

Mounjaro Discount Code UK Pharmacy – £20 off first order using code WEIGHTLOSSNEW

Published on: June 03, 2026

Searching for a genuine mounjaro discount code uk pharmacy offer? Cured Pharmacy provides transparent upfront pricing on Mounjaro (tirzepatide) weight loss injections from £124.99, with code WEIGHTLOSSNEW offering significant savings. Our UK-registered clinical team provides free online consultations, and all Mounjaro pens are genuine MHRA-licensed medicines dispensed by GPhC-registered pharmacists.

How Mounjaro (Tirzepatide) Works for Weight Loss

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, creating a synergistic effect on appetite regulation and metabolic function.

In the landmark SURPASS-2 trial, participants receiving the 15mg maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks, compared to 15.8% with 2.4mg semaglutide [1]. This dual-action mechanism helps reduce hunger signals, slow gastric emptying, and improve insulin sensitivity, making it one of the most effective pharmaceutical interventions for obesity currently available in the UK.

The medication works by mimicking natural gut hormones released after eating, signalling fullness to the brain and helping patients feel satisfied with smaller portions. Clinical trials consistently demonstrate that tirzepatide produces dose-dependent weight loss, with higher maintenance doses yielding greater average reductions in body weight when combined with lifestyle modifications [2].

Mounjaro Discount Code UK Pharmacy: What You Need to Know

At Cured Pharmacy, we believe in transparent pricing for weight loss treatments. Our discount code WEIGHTLOSSNEW provides genuine savings on Mounjaro prescriptions, bringing the starting price to £124.99 for eligible patients following clinical assessment. Unlike some promotional offers that apply only to first purchases, our pricing structure remains competitive across ongoing treatment cycles.

All Mounjaro prescriptions dispensed through Cured Pharmacy require completion of a free online consultation with a UK-registered prescriber. This clinical assessment typically takes under three minutes and evaluates your medical history, current medications, BMI, and weight loss goals to determine whether tirzepatide is appropriate and safe for you. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees every prescription to ensure clinical safety and regulatory compliance.

It's important to understand that legitimate UK pharmacies cannot dispense prescription-only medicines like Mounjaro without a valid prescription from a qualified prescriber. Any website offering tirzepatide without a clinical assessment is operating illegally and may be supplying counterfeit or unsafe medications. Cured Pharmacy is fully registered with the General Pharmaceutical Council (GPhC Registration Number 9012511), ensuring you receive genuine UK-licensed medicines with proper clinical oversight.

How to Apply Your Mounjaro Discount Code

To access your discounted Mounjaro pricing, simply complete the free online consultation through our weight loss assessment portal. During the checkout process, the discount code WEIGHTLOSSNEW will be applied automatically to eligible prescriptions. Your final price depends on the dose prescribed by your UK clinician, starting from £135.00 for maintenance therapy.

After your prescriber approves your Mounjaro prescription, our pharmacy team dispenses your medication in 100% discreet packaging with next-day delivery options available across the UK. We provide clear dosing instructions, injection technique guidance, and ongoing support throughout your weight loss journey.

Mounjaro vs Wegovy vs Saxenda: UK Price and Efficacy Comparison

UK patients now have access to three injectable GLP-1 receptor agonist treatments for weight management: Mounjaro (tirzepatide), Wegovy (semaglutide), and Saxenda (liraglutide). Each medication has distinct mechanisms, dosing schedules, and clinical efficacy profiles that influence treatment selection.

Head-to-head clinical data shows tirzepatide producing superior weight loss outcomes compared to semaglutide. In the SURPASS-2 trial, participants on tirzepatide 15mg achieved 6.7 percentage points greater body weight reduction than those on semaglutide 1mg over 40 weeks [1]. However, individual response varies, and some patients may experience better tolerability or results with alternative treatments.

Saxenda requires daily injections compared to the once-weekly administration of Mounjaro and Wegovy, which some patients find less convenient for long-term adherence. Clinical trials demonstrate that liraglutide (Saxenda) produces average weight loss of 5-7% of initial body weight, whilst semaglutide and tirzepatide typically achieve 15-22% reductions respectively [3]. Your UK prescriber will recommend the most appropriate option based on your medical history, weight loss goals, previous treatment responses, and individual circumstances.

Choosing the Right Weight Loss Injection

Treatment selection depends on multiple factors beyond efficacy data. Patients with certain cardiovascular risk factors may benefit from semaglutide's proven cardiovascular outcomes data, whilst those seeking maximum weight loss potential may be better suited to tirzepatide therapy. Cost considerations, injection frequency preferences, and side effect profiles also influence decision-making.

During your consultation, our UK prescribers assess your complete medical picture, including any contraindications, concurrent medications, and previous weight loss attempts. This personalised approach ensures you receive the safest and most effective treatment for your individual needs, with ongoing monitoring and dose adjustments as required.

Clinical Evidence: SURPASS Trial Results for Tirzepatide

The SURPASS clinical trial programme represents the most comprehensive evaluation of tirzepatide's efficacy and safety for weight management. SURPASS-1 through SURPASS-5 enrolled over 6,000 participants with obesity or overweight with weight-related complications, demonstrating consistent and substantial weight loss across diverse populations [2].

In SURPASS-3, which compared tirzepatide directly against insulin degludec in patients with type 2 diabetes, participants receiving the 15mg tirzepatide dose achieved mean weight reductions of 13.9kg (approximately 2.2 stone) compared to 2.3kg weight gain in the insulin group over 52 weeks [4]. Importantly, these results were achieved alongside significant improvements in glycaemic control, with 55% of tirzepatide-treated participants achieving HbA1c below 5.7% (normal range).

The SURMOUNT-1 trial specifically evaluated tirzepatide in adults without diabetes, demonstrating that 91% of participants on the 15mg dose achieved at least 5% body weight reduction, with 57% achieving 20% or greater weight loss over 72 weeks [5]. These outcomes substantially exceed the efficacy thresholds established for other pharmaceutical weight loss interventions and approach results previously seen only with bariatric surgery.

Safety data from the SURPASS programme shows tirzepatide is generally well-tolerated, with gastrointestinal side effects (nausea, diarrhoea, constipation) being the most commonly reported adverse events. These effects typically occur during dose escalation and diminish over time as patients adjust to treatment [2].

Mounjaro Dosing Schedule and What to Expect

Mounjaro treatment follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. The standard UK dosing schedule begins with 2.5mg once weekly for four weeks, serving as an initial tolerability dose rather than a therapeutic maintenance level.

After the first month, your prescriber will typically increase your dose to 5mg weekly for four weeks, then 7.5mg weekly for four weeks, with further escalations to 10mg, 12.5mg, or 15mg depending on your response and tolerability. This gradual titration allows your body to adapt to the medication's effects and significantly reduces the likelihood of severe nausea or vomiting that can occur with rapid dose increases.

Each Mounjaro KwikPen contains four pre-filled doses at the prescribed strength, administered subcutaneously (under the skin) into the abdomen, thigh, or upper arm. The injection process takes seconds and uses ultra-fine needles that most patients find comfortable. We provide comprehensive injection technique guidance with every prescription, including video demonstrations and written instructions.

Most patients begin noticing appetite reduction and early weight loss within the first 2-4 weeks of treatment, with progressive results over subsequent months. Clinical trials show that maximum weight loss typically occurs between 60-72 weeks of continuous treatment, though individual timelines vary [5]. Mounjaro works most effectively when combined with a reduced-calorie diet and increased physical activity, as evaluated and supported by your prescriber.

Managing Side Effects During Dose Escalation

Gastrointestinal side effects are most common during the first few weeks after each dose increase. Practical strategies to minimise discomfort include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection on the same day each week to maintain consistent medication levels.

If you experience persistent or severe side effects, contact your prescriber before your next dose increase. Some patients benefit from extending the duration at a particular dose level before escalating further, whilst others may find their optimal maintenance dose below the maximum 15mg level. Our clinical team provides ongoing support throughout your treatment journey to optimise both efficacy and tolerability.

Who Can Use Mounjaro: Eligibility and Safety Considerations

In the UK, Mounjaro is licensed for weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. NICE guidance supports the use of GLP-1 receptor agonists as part of a specialist weight management service for eligible patients [6].

Certain medical conditions preclude the use of tirzepatide. Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as GLP-1 receptor agonists have been associated with thyroid C-cell tumours in rodent studies (though no causal relationship has been established in humans). The medication should be used with caution in patients with severe gastrointestinal disease, history of pancreatitis, or severe renal impairment.

During your consultation, our UK prescribers conduct a thorough medical history review, including current medications that may interact with tirzepatide. Particular attention is paid to diabetes medications, as combining Mounjaro with insulin or sulfonylureas increases the risk of hypoglycaemia and may require dose adjustments. Women who are pregnant, planning pregnancy, or breastfeeding should not use Mounjaro, as insufficient safety data exists for these populations.

Our clinical assessment also evaluates your previous weight loss attempts, current eating patterns, mental health history, and realistic expectations for treatment. Successful weight management with Mounjaro requires commitment to lifestyle modifications alongside pharmaceutical intervention. Patients with untreated eating disorders or unrealistic expectations may not be suitable candidates and may benefit from alternative approaches or additional psychological support before starting medication.

Ongoing Monitoring and Follow-Up Care

After initiating Mounjaro treatment, regular follow-up consultations ensure safe and effective therapy. Our prescribers monitor your weight loss progress, side effect profile, and any changes in your medical status that might affect treatment continuation. Most patients require ongoing prescriptions at monthly intervals, with dose adjustments made based on individual response and tolerability.

We recommend patients also maintain regular contact with their NHS GP, particularly if you have concurrent medical conditions requiring monitoring such as diabetes or cardiovascular disease. Weight loss achieved with Mounjaro can significantly improve these conditions, potentially allowing reduction in other medications under appropriate medical supervision.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Mounjaro is a prescription-only medicine that may not be suitable for everyone. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.